



Medical Cannabis for Chronic Nonmalignant Pain Management

Maha Hameed¹ · Sakshi Prasad¹ · Esha Jain¹ · Bekir Nihat Dogrul¹ · Ahmad Al-Oleimat¹ · Bidushi Pokhrel¹ · Selia Chowdhury¹ · Edzel Lorraine Co¹ · Saloni Mitra¹ · Jonathan Quinonez² · Samir Ruxmohan³ · Joel Stein⁴

Accepted: 23 January 2023 / Published online: 10 March 2023

© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023

Abstract

Purpose of Review Cannabis has been used since ancient times for medical and recreational research. This review article will document the validity of how medical cannabis can be utilized for chronic nonmalignant pain management.

Recent Findings Current cannabis research has shown that medical cannabis is indicated for symptom management for many conditions not limited to cancer, chronic pain, headaches, migraines, and psychological disorders (anxiety and post-traumatic stress disorder). Δ^9 -Tetrahydrocannabinol (THC) and cannabidiol (CBD) are active ingredients in cannabis that modulate a patient's symptoms. These compounds work to decrease nociception and symptom frequency via the endocannabinoid system. Research regarding pain management is limited within the USA as the Drug Enforcement Agency (DEA) classifies it as a schedule one drug. Few studies have found a limited relationship between chronic pain and medical cannabis use.

Summary A total of 77 articles were selected after a thorough screening process using PubMed and Google Scholar. This paper demonstrates that medical cannabis use provides adequate pain management. Patients suffering from chronic nonmalignant pain may benefit from medical cannabis due to its convenience and efficacy.

Keywords Cannabis · Medical marijuana · Chronic nonmalignant pain · Opioids

This article is part of the Topical Collection on *Alternative Treatments for Pain Medicine*

✉ Jonathan Quinonez
equinonezmedicine@gmail.com

Maha Hameed
mwhameed2016@gmail.com

Sakshi Prasad
sakshiprasad8@gmail.com

Esha Jain
eshajain67@gmail.com

Bekir Nihat Dogrul
nihatdogrul@outlook.com

Ahmad Al-Oleimat
A.oleimat@outlook.com

Bidushi Pokhrel
pbidushi@gmail.com

Selia Chowdhury
chowdhury.selia@gmail.com

Edzel Lorraine Co
edzelco@gmail.com

Saloni Mitra
saloni.mitra2000@gmail.com

Samir Ruxmohan
ruxmohan@yahoo.com

Joel Stein
ommdoc@aol.com

¹ Larkin Community Hospital, South Miami, FL, USA

² Department of Osteopathic Neuromuscular Medicine/Neurology, Canna MD & Larkin Community Hospital, Miami, FL, USA

³ Department of Neurocritical Care, UT Southwestern, Dallas, TX, USA

⁴ Department of Osteopathic Neuromuscular Medicine/Neurology, Larkin Community Hospital, Miami, FL, USA

Introduction

Due to its association with decreased quality of life, opioid dependence, and negative impact on mental health, chronic pain is a common reason adults seek medical attention. Chronic pain is assessed through the experience of patients, who, when asked, “how often have you experienced pain in the past three months?”, respond with “most days” or “every day.” According to the Centers for Disease Control and Prevention (CDC), in 2019, approximately 20.4% of adults in the USA had chronic pain, while 7.4% reported high-impact chronic pain. Chronic pain was highest among females (8.5%) and patients aged ≥ 65 . Non-Hispanic adults experienced more chronic pain (23.6%) and high-impact chronic pain (8.4%) in the past 3 months compared to their Hispanic and non-Hispanic Black/Asian counterparts [1].

The current standard of treatment for chronic pain involves opioid analgesics, which can be problematic due to side effects ranging from severe constipation to respiratory depression and opioid dependence. The opioid epidemic poses a formidable challenge. The World Health Organization (WHO) estimates that approximately 0.5 million deaths yearly are attributable to drug use; more than 70% are due to opioid use [2]. Compounds derived from the *Cannabis sativa* and *Cannabis indica* plants have been studied and seen to have a therapeutic role in pain management while simultaneously decreasing opioid prescriptions among patients with long-term conditions such as chronic kidney disease [3, 4].

In 1996, the California Compassionate Use Act was among the first state policies legalizing the use of cannabis (primarily in the context of analgesia and antiemesis in patients with AIDS) [5]. California was the first state in 1996 to legalize the California Compassionate Use Act, which allowed for the use of cannabis (primarily in the context of analgesia and antiemesis in patients with AIDS) [5]. Thirty-eight US states and the DC in 2017 permitted the use of medical cannabis [6], with more than 2.1 million people with medical cannabis licenses in the legalized medical cannabis states. Out of these licensed individuals, 62% had chronic pain accounting for the license-qualifying condition throughout the USA [7]. Both tetrahydrocannabinol (THC) and cannabidiol (CBD) are commonly used for chronic pain management in patients with advanced cancer, chronic pelvic pain, multiple sclerosis spasticity, fibromyalgia, and sleep apnea, as well as for adjunctive traditional analgesic therapy [8–10]. In the USA, Canada, and the Netherlands, chronic nonmalignant pain is the most cited reason for the use of cannabis for medical purposes [11••]. The present review attempts to highlight the benefits, use, forms, and limitations of cannabis use in managing chronic pain and see how it compares to opioids for a conclusive treatment approach.

Mechanism of Action

Cannabis, also known as marijuana, has an age-old history of recreational uses but is increasingly getting substituted with opioids for pain therapy. Multiple molecular and pre-clinical studies have been performed that support the antinociceptive role that cannabis plays [12, 13]. However, in the human picture, there is a lack of strong evidence for us to use cannabis-based medications in broad clinical practice as pain therapy [14].

The endocannabinoid system (ECS) is believed to play an integral role in pain modulation. It works by various mechanisms involving neuro- and immuno-modulation at the supra-spinal, spinal, and peripheral levels [15–17]. The enzymes responsible for the synthesis, metabolism, and regulation of the endocannabinoid ligands, along with the cannabinoid receptors (CB1/CB2), comprise the endocannabinoid system [15–18]. There are three broad categories of cannabinoids that are accepted in the literature: endogenous cannabinoids, which are derived from arachidonic acid, phytocannabinoids (THC and CBD), which are derived from the cannabis plant (*Cannabis sativa*), and synthetic cannabinoids (dronabinol and nabilone), which are artificially produced compounds targeting various elements of the endocannabinoid system [16, 19].

Endocannabinoid Receptors

A class of endogenous ligands derived from arachidonic acid that exert their effect on the cannabinoid receptors is termed endocannabinoids. This group's major lipid mediators are arachidonoyl ethanolamide (anandamide or AEA) and 2-arachidonoylglycerol [20]. Palmitoylethanolamide (PEA) and oleoyl ethanolamide (OEA) are structural analogs also belonging to endocannabinoids that interact with nuclear receptors (PPARs and TRPV1) and G-protein-coupled receptors (GPR55, GPR92, and GPR18) [21, 22]. These ligands are involved in several physiological systems including mood, memory, satiety, female reproduction, immune, gastrointestinal, cardiovascular system, and pain (including neuropathic) [15, 20].

Cannabinoid receptors CB1 and CB2 are present in neurons throughout the central and peripheral nervous system; they act on immune and non-neuronal cells in both the central and peripheral nervous system and work through modulation of G-protein-coupled receptors (GPCR) [8, 23]. CB1 receptors can be located in the CNS, presynaptic terminals of peripheral pain receptors, neurons in the dorsal root ganglion, smooth muscle, adipocytes, spinal cord, and myocardium [24]. In contrast, CB2 receptors are present in the non-neuronal cells of CNS (macrophages, microglia,

and astrocytes) and organs with immune and hematopoietic function (leukocytes, spleen, tonsils, lung, testes, and brain) [19, 23, 25].

It is hypothesized that CB1 receptors inhibit excessive neuronal excitation and activity and thus maintain homeostasis [26]. By binding to the CB1 presynaptic receptor, cannabinoids inhibit the calcium influx, decreasing the release of neurotransmitters and thereby decreasing/modulating pain [27]. The primary neurotransmitters inhibited by activation of the CB1 receptor are γ -aminobutyric acid (GABA) and glutamate; albeit acetylcholine, noradrenaline, dopamine, 5-hydroxytryptamine (5-HT), D-aspartate, cholecystokinin, and others have also been found to play a role [27]. CB1 receptors also have a role in the spinal and supraspinal levels by suppressing nociception in the spinal cord dorsal horn and activating descending inhibitory pathways in the raphe nucleus periaqueductal gray. In contrast, activation of the CB2 receptor reduces inflammation pain. It causes hyperalgesia through complex interactions within the ECS system and altered release of pro-inflammatory cytokines like interferon-gamma, interleukins, and tumor necrosis factor-alpha [25–27].

Different Forms of Cannabis and Patient Preferences

Many existing studies in the broader literature have reviewed different forms of cannabis used by patients suffering from chronic pain. In 2021, Lovecchio et al. conducted an online survey on 214 patients with spine-related chronic pain. The study reported that only 25.2% of patients used medical cannabis for potential pain relief. More males (58%) participated in the survey than female patients. Analysis of consumption patterns revealed that the most common formulations used by patients were oil and tincture (65%), with topical creams (37%) and edible methods (33%) being the next most common. This paper also reported that approximately one-third of patients (19 out of 54) used more than one form [28].

A recent cross-sectional study was conducted by Fitzcharles et al. to examine the prevalence and characteristics of medical cannabis use in fibromyalgia patients in Canada. Patients were asked about previous and current cannabis use, frequency, method of use, the daily amount used in grams, and the reason for discontinuation, if applicable. From the survey, 28 (23.9%) of fibromyalgia patients had tried medical cannabis to treat their chronic pain, with more than half reporting continued use. Of the current users, cigarette smoking was the primary method of use, followed by vaporization, oil capsules, and cannabis-infused food (i.e., edibles) [29].

In an observational prospective cohort study by Meng et al., patients with chronic pain seeking medical cannabis

were investigated. Each patient was required to fill out a baseline questionnaire on their initial visit and follow-up questionnaires at 3, 6, and 12 months. A total of 757 participants completed baseline questionnaires. The majority of them were females (61.6%). At baseline, the most common form of use was dried cannabis (68.2%); however, the combination of dried cannabis and cannabis oil became consumed most commonly [30].

In a 2021 survey by Schilling et al., participants were asked about their demographics, awareness, experience, and knowledge of CBD. Participants were also questioned regarding the type of products they used, choosing more than one form of use. Inhaled/smoked products were the most common type of products used (62.9%), followed by edibles (54.3%), oral tinctures (52.3%), ointment/oil, and cream (49.7%) [31].

Vidot et al. (2020) conducted a cross-sectional study in the USA to analyze the patterns of cannabis use among medical cannabis users with chronic conditions and how those changed due to the COVID-19 pandemic. A total of 1202 participants completed an online-based questionnaire (52% were males). The most common routes of administration were inhalational and as follows: smoking (39%), vaporization (24.1%), and smoking via joints (without tobacco) (18.8%). The results also reported that 16% of participants changed their route of administration due to the pandemic. In comparison, after the declaration of COVID-19 as a pandemic, the nonsmoking route was the most common administration method: edibles (31.4%), tinctures (10.9%), and pills (4.2%). This route is primarily attributed to the fact that many inhalational smokers (59.2%) have stopped sharing their cigarettes and electronic vaporizing devices since the declaration of the pandemic [32].

In a 2020 cross-sectional study conducted by Sznitman et al., 125 adult chronic pain patients participated in the survey (51.2% were females). When asked about the modes of cannabis administration they use, survey participants, who could indicate multiple preferences, reported smoking (68.6%) as the most common route, followed by oil extracts (21.4%) and vaporization (20.0%) [33].

Most persons with chronic pain choose a combination of indica and sativa to alleviate their symptoms [34]. Males and females, those who solely used cannabis for medical reasons and those who supported both medical and recreational use, and rookie and expert users all had similar cannabis strain preferences [34].

The majority of patients preferred medical cannabis products with balanced THC: CBD ratios (37%) or high CBD formulations (46%) and only a minority (17%) preferring high THC products (moderate certainty) [35]. Women, rookie users, and those who solely endorsed cannabis for medicinal purposes preferred products with low THC and high CBD ratios, whereas males, those who endorsed

cannabis for medical and recreational purposes, and experienced users chose products with equal THC:CBD ratios [36].

The preference for the route of administration was influenced by sex, the reason for usage, and previous cannabis experience (moderate certainty) [37]. Women preferred tinctures and topical medicines to vaporizing or smoking compared to male patients [36]. Compared to rookie users who favored vaporizing, experienced cannabis users endorsed several methods of administration [36]. Most patients with advanced life-limiting illnesses preferred oral (non-inhaled) medical cannabis preparations [38].

Legalization of Cannabis

The medical and recreational consumption of cannabis in the USA has a complex history of medical, legal, economic, and social aspects. Cannabis laws in states are closely tied to public perceptions [39]. In the last few decades, the perception that cannabis may not be harmful and has medical benefits has grown in society [40, 41]. Furthermore, support for the legalization of medical cannabis has increased significantly among health professionals and medical students [42].

As of 2021, 36 US states and the DC have passed laws legalizing medical, while 18 US states and the DC have passed laws regulating the legalization of recreational marijuana [6]. There are also medical cannabis programs in other countries such as Canada, Germany, Italy, Israel, the Netherlands, UK, Uruguay, Brazil, Colombia, and Thailand [43, 44]. Approximately 72% of the US population now lives in states where medical cannabis is legalized [6, 45]. About 10% of cannabis users in the USA use it to treat a medical condition [46].

Although many states have legalized medical, cannabis use still violates federal law. Cannabis, defined by the US Drug Enforcement Administration (DEA) as a schedule I substance, which means no currently accepted medical use, causes federal and state laws to become dichotomous [47]. Although the legalization of medical cannabis continues rapidly in the states, the DEA reaffirmed that marijuana is a schedule I substance in 2016 [48].

There are various arguments supporting and opposing the legalization of medical cannabis. Generally, these arguments are contradictory, positing that the legalization of medical cannabis will either increase or decrease marijuana use, provide stricter regulation, increase or decrease public safety, and more [49•]. Opponents argue that cannabis use in early adolescence is associated with future academic failure. Therefore, the possibility that marijuana use may increase in the younger age group is a constant topic of discussion [50].

There is a significant difference between non-legal and decriminalized states in calling poison centers for the pediatric

age group [51]. Legalizing medical cannabis may increase the prevalence of marijuana use in the adult age group, but studies are mixed [51, 52]. In addition, many variables such as genetic differences of marijuana plants, variations in the prices, and the potency of the products are associated with the mixed results of studies in the medical literature [53]. Another critical question is how marijuana use will affect opioid use. Although studies show that marijuana legalization can reduce the opioid epidemic, research is conflicting [48, 54].

According to the states where medical cannabis is legal, cannabis is used for many diseases such as chronic pain, seizures, migraine, cachexia, spasticity, post-traumatic stress disorder, irritable bowel syndrome, inflammatory bowel syndrome, and glaucoma [55, 56]. However, the FDA has approved only dronabinol and nabilone (laboratory derived) for chemotherapy-related nausea and AIDS-related weight loss and cannabidiol (plant derived) for Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex-associated seizures [40, 57].

The plight of the opioid epidemic has prompted physicians to seek other ways to manage chronic pain, and medical cannabis may be an alternative to opioids for chronic pain [58]. One of the most approved indications in states where medical cannabis is legalized and the most common reason for patients to demand cannabis is chronic pain [23, 58]. There is data that marijuana use is associated with decreasing prescription of other drugs for pain [52].

The increasing number of medical cannabis laws globally requires health professionals to know cannabis in medical, legal, logistic, and economic aspects. The illegality of medical cannabis at the federal level is an issue that needs to be discussed with patients, as legal complexity may arise in the circumstances such as crossing state borders [23]. Physicians should also discuss the economic facets of medical marijuana with patients, as medical cannabis is rarely covered by insurance [46].

Despite state and federal law dichotomy, physicians are legally protected under *Conant v. Walter*'s decision as they suggest medical cannabis as a professional recommendation [55]. The unstandardized cannabinoid preparations, the lack of a common opinion on dosages, the little known about the side effect profile, and the lack of sufficient data on drug interactions appear as general discussions around legalization for medical purposes [58]. In particular, the use of medical cannabis for chronic pain can provide effective results for both pain management and slowing down the opioid epidemic.

Comparison with Opioids

Opioids have been the mainstay of intractable chronic pain management for a long time. However, the adverse effects of their use and increased mortality rates due to

their overdose are issues of concern. Cannabis extracts and their synthetic preparations slowly replace opioids for applications in various conditions involving chronic pain and inflammation [59]. In emerging studies, cannabis is as effective as or even better than opioids in relieving chronic pain of multiple origins [60••, 61, 62].

A meta-analysis conducted by Busse et al. found no difference in the extent of pain relief between opioids and nabilone, a synthetic cannabinoid (73 patients; mean difference -0.13 cm [95% CI, -1.04 to 0.77 cm] on the 10-cm Visual Analog Scale for pain, $P=0.77$), indicating that cannabinoids could be as effective as opioids in pain relief [60••]. Another study conducted by Sohler et al. among HIV-infected individuals demonstrated that cannabis use was significantly associated with lower odds of opioid use as prescription analgesics (adjusted odds ratio = 0.57 (95% C.I. 0.38 – 0.87) [63]. These findings provide evidence regarding the efficacy of cannabis in mitigating pain alongside the widely prescribed opioids.

There, however, is limited evidence available to define standard comparable doses of cannabinoids and opioids to achieve the desired control of pain. One study by Noyes et al. attempted to compare the doses of tetrahydrocannabinol (THC) and codeine, wherein 10 mg of THC was slightly less effective than 60 mg of codeine, and 20 mg of THC was slightly more effective than 120 mg of codeine in controlling chronic cancer pain [64]. Another single-patient study observing the analgesic effects of oral 5 mg THC, 50 mg codeine, and placebo concluded that both drugs were significantly more effective than placebo in controlling multiple sclerosis-related pain [61].

Many studies have also shown that cannabis use has helped reduce opioid dependence greatly and that cannabinoids could be the next big substitutes for them, facilitating the global burden of increasing opioid addiction and fatalities. A survey performed by Boehnke et al. revealed that the use of medical cannabis was associated with a 64% reduction in opioid use in 118 subjects, minimized side effects of medications, and improved quality of life (45%) [65]. Another study performed to analyze the effect of cannabis on pain and quality-of-life outcomes in chronic pain found that along with the improvement in the pain severity score (7.50 [95% CI 6.75 – 7.75] to 6.25 [95% CI 5.75 – 6.75], $P<0.001$), opioid consumption at follow-up decreased by 44% ($P<0.001$) [66]. In an extensive study from Israel encompassing 3619 participants, only 4.6% continued to experience severe pain ($>7/10$) after 6 months of cannabinoid mixture administration compared to 52.6% at baseline. The use of opioids ceased in 36% of patients, a decrease in opioid doses was reported by 10% of patients, and an opioid increase was reported by only 1% of patients [67].

Opioids have adverse effects in much greater proportion than cannabinoids. Most patients experience

gastrointestinal or central nervous system-related adverse events, most commonly constipation, nausea, and somnolence. Cognitive impairment and dizziness are less prevalent but reported [68]. Dependence and respiratory depression are effects of even more concern. On the other hand, cannabinoids usually have various temporary side effects, which eventually subside with the development of tolerance. Vomiting, urinary tract infection, or even relapse of multiple sclerosis has been reported in a systematic review by Wang et al. as some serious side effects [69]. THC, a psychoactive constituent of cannabis, has been implicated in cardiovascular disease, acute pancreatitis, cannabinoid hyperemesis syndrome, and particularly in pregnancy, and is associated with an increased risk of neonatal morbidity and death [65, 70].

Conclusions

Patients often seek medical consultations most commonly because of having intolerable chronic pain. Medications such as NSAIDs or opioids are being used to relieve such pain. However, long-term use of these medications can also cause adverse effects on health. Several studies have been done regarding cannabis as an alternative for chronic pain. Some patients were reported to get relief from cannabis consumption through various routes, and the use of it has been legalized, too, in some states in the USA and countries like Germany, Italy, the Netherlands, UK, Australia, Uruguay, Brazil, Colombia, Chile, Thailand, and Jamaica. Compared with opioids, studies show that cannabis use has lesser adverse effects, and it could even lessen opioid dependence. As clinicians, it is good to determine the primary purpose of using cannabis before prescribing it to patients to weigh the advantages and disadvantages that underlie it. Evaluating patients very well about the use of cannabis is important to decide whether to prescribe such medication or just sort to other alternative ways of managing pain to render the best possible patient care.

Author Contribution Conceptualization: M.H. and J.Q.; writing (original draft preparation): M.H., S.P., E.J., B.N.D., A.A., B.P., S.C., E.L.O., and S.M.; writing (review and editing): M.H., S.P., and J.Q.; supervision: J.Q., S.R., W.C., and J.S.; All authors have read and agreed to the published version of the manuscript.

Data Availability The authors declare that data supporting the findings of this study are available within the article.

Compliance with Ethical Standards

Conflict of Interest The authors declare no competing interests.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Zelaya CE, Dahlhamer JM, Lucas JW, Connor EM. Chronic pain and high-impact chronic pain among U.S. adults, 2019. *NCHS Data Brief*. 2020 Nov;(390):1–8.
2. World Health Organization. Opioid overdose [Internet]. 2021 [cited 2022 May 12]. Available from: <https://www.who.int/news-room/fact-sheets/detail/opioid-overdose>
3. Blake A, Wan BA, Malek L, DeAngelis C, Diaz P, Lao N, et al. A selective review of medical cannabis in cancer pain management. *Ann Palliat Med*. 2017;6(Suppl 2):S215–22.
4. Rein JL. The nephrologist's guide to cannabis and cannabinoids. *Curr Opin Nephrol Hypertens*. 2020;29(2):248–57.
5. Carr D, Schatman M. Cannabis for chronic pain: not ready for prime time. *Am J Public Health*. 2019;109(1):50–1.
6. National Conference of State Legislatures. State medical cannabis laws [Internet]. [cited 2022 May 12]. Available from: <http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx>
7. Boehnke KF, Scott JR, Litinas E, Sisley S, Williams DA, Clauw DJ. High-frequency medical cannabis use is associated with worse pain among individuals with chronic pain. *J Pain*. 2020;21(5–6):570–81.
8. Manz J, Hyakutake M, Kelly E. Calling for openness to the study of cannabis use in chronic pelvic pain. *J Obstet Gynaecol Can*. 2021;43(5):611–3.
9. Likhitsathian S, Edelstein OE, Srisurapanont M, Zolotov Y, Karawekpanyawong N, Reznik A, et al. Cross national comparison of medical students' attitudes and beliefs about medical cannabis and its application for pain management. *Complement Ther Med*. 2021;59: 102720.
10. Gonen T, Amital H. Cannabis and cannabinoids in the treatment of rheumatic diseases. *Rambam Maimonides Med J*. 2020 Jan 30;11(1).
11. ●● Campbell G, Hall WD, Peacock A, Lintzeris N, Bruno R, Larance B, et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. *Lancet Public Health*. 2018 Jul;3(7):e341–50. **This paper highlights the evidence-based statement of chronic nonmalignant pain being the most common reason for cannabis use for medical purposes.**
12. Hasanein P, Teimuri FM. Effects of URB597 as an inhibitor of fatty acid amide hydrolase on WIN55, 212-2-induced learning and memory deficits in rats. *Pharmacol Biochem Behav*. 2015;131:130–5.
13. Shang Y, Tang Y. The central cannabinoid receptor type-2 (CB2) and chronic pain. *Int J Neurosci*. 2017;127(9):812–23.
14. Lötsch J, Weyer-Menkoff I, Tegeder I. Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings. *Eur J Pain*. 2018;22(3):471–84.
15. Scotter EL, Abood ME, Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. *Br J Pharmacol*. 2010;160(3):480–98.
16. Lee G, Grovey B, Furnish T, Wallace M. Medical cannabis for neuropathic pain. *Curr Pain Headache Rep*. 2018;22(1):8.
17. Maldonado R, Baños JE, Cabañero D. The endocannabinoid system and neuropathic pain. *Pain*. 2016;157(Suppl 1):S23–32.
18. Wang J, Ueda N. Biology of endocannabinoid synthesis system. *Prostaglandins Other Lipid Mediat*. 2009;89(3–4):112–9.
19. Lucas P. Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain. *J Psychoactive Drugs*. 2012;44(2):125–33.
20. Rodríguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. *Alcohol Alcohol*. 2005 Feb;40(1):2–14.
21. Thabuis C, Tissot-Favre D, Bezelgues JB, Martin JC, Cruz-Hernandez C, Dionisi F, et al. Biological functions and metabolism of oleylethanolamide. *Lipids*. 2008;43(10):887–94.
22. Godlewski G, Offertáler L, Wagner JA, Kunos G. Receptors for acylethanolamides-GPR55 and GPR119. *Prostaglandins Other Lipid Mediat*. 2009;89(3–4):105–11.
23. Ebbert JO, Scharf EL, Hurt RT. Medical cannabis. *Mayo Clin Proc*. 2018;93(12):1842–7.
24. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol Rev*. 2006;58(3):389–462.
25. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. *Br J Pharmacol*. 2008;153(2):319–34.
26. Pertwee RG. The diverse CB₁ and CB₂ receptor pharmacology of three plant cannabinoids: Δ^9 -tetrahydrocannabinol, cannabidiol and Δ^9 -tetrahydrocannabivarin: Δ^9 -THC, CBD and Δ^9 -THCV. *Br J Pharmacol*. 2008;153(2):199–215.
27. Jensen B, Chen J, Furnish T, Wallace M. Medical marijuana and chronic pain: a review of basic science and clinical evidence. *Curr Pain Headache Rep*. 2015;19(10):50.
28. Lovecchio F, Langhans MT, Bennett T, Steinhaus M, Premkumar A, Cunningham M, et al. Prevalence of cannabidiol use in patients with spine complaints: results of an anonymous survey. *Int J Spine Surg*. 2021;15(4):663–8.
29. Fitzcharles MA, Rampakakis E, Sampalis JS, Shir Y, Cohen M, Starr M, et al. Use of medical cannabis by patients with fibromyalgia in Canada after cannabis legalisation: a cross-sectional study. *Clin Exp Rheumatol*. 2021;39(3):115–9.
30. Meng H, Page MG, Ajrawat P, Deshpande A, Samman B, Dominicis M, et al. Patient-reported outcomes in those consuming medical cannabis: a prospective longitudinal observational study in chronic pain patients. *Can J Anesth/J Can Anesth*. 2021;68(5):633–44.
31. Schilling JM, Hughes CG, Wallace MS, Sexton M, Backonja M, Moeller-Bertram T. Cannabidiol as a treatment for chronic pain: a survey of patients' perspectives and attitudes. *JPR*. 2021;14:1241–50.
32. Vidot DC, Islam JY, Marlene Camacho-Rivera, Harrell MB, Rao DR, Chavez JV, et al. The COVID-19 cannabis health study: results from an epidemiologic assessment of adults who use cannabis for medicinal reasons in the United States. *Journal of Addictive Diseases*. 2020 Dec 1;39(1):26–36.
33. Sznitman SR, Vulfsons S, Meiri D, Weinstein G. Medical cannabis and cognitive performance in middle to old adults treated for chronic pain. *Drug Alcohol Rev*. 2021;40(2):272–80.
34. Zeng L, Lytvyn L, Wang X, Kithulegoda N, Agterberg S, Shergill Y, et al. Values and preferences towards medical cannabis among people living with chronic pain: a mixed-methods systematic review. *BMJ Open*. 2021;11(9):e050831.
35. Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ?N of 1? studies. *Anaesthesia*. 2004;59(5):440–52.

36. Boehnke KF, Scott JR, Litinas E, Sisley S, Clauw DJ, Goesling J, et al. Cannabis use preferences and decision-making among a cross-sectional cohort of medical cannabis patients with chronic pain. *J Pain*. 2019;20(11):1362–72.
37. Piper BJ, Beals ML, Abess AT, Nichols SD, Martin MW, Cobb CM, et al. Chronic pain patients' perspectives of medical cannabis. *Pain*. 2017;158(7):1373–9.
38. Gallagher R, Best JA, Fyles G, Hawley P, Yeomans W. Attitudes and beliefs about the use of cannabis for symptom control in a palliative population. *Journal of Cannabis Therapeutics*. 2003;3(2):41–50.
39. Chiu V, Leung J, Hall W, Stjepanović D, Degenhardt L. Public health impacts to date of the legalisation of medical and recreational cannabis use in the USA. *Neuropharmacology*. 2021;193: 108610.
40. Tanco K, Dumlao D, Kreis R, Nguyen K, Dibaj S, Liu D, et al. Attitudes and beliefs about medical usefulness and legalization of marijuana among cancer patients in a legalized and a nonlegalized state. *J Palliat Med*. 2019;22(10):1213–20.
41. Meng H, Dai T, Hanlon JG, Downar J, Alibhai SMH, Clarke H. Cannabis and cannabinoids in cancer pain management. *Curr Opin Support Palliat Care*. 2020;14(2):87–93.
42. Weisman JM, Rodríguez M. A systematic review of medical students' and professionals' attitudes and knowledge regarding medical cannabis. *J Cannabis Res*. 2021;3(1):47.
43. Ruheel MA, Gomes Z, Usman S, Homayouni P, Ng JY. Facilitators and barriers to the regulation of medical cannabis: a scoping review of the peer-reviewed literature. *Harm Reduct J*. 2021;18(1):106.
44. Hawley P, Gobbo M, Afghari N. The impact of legalization of access to recreational cannabis on Canadian medical users with cancer. *BMC Health Serv Res*. 2020;20(1):977.
45. United States Census Bureau. Explore census data [Internet]. 2021 [cited 2022 May 12]. Available from: <https://data.census.gov/cedsci/table?q=Population%20Total&tid=DECENNIALPL2020.P1&tp=false>
46. Levinsohn EA, Hill KP. Clinical uses of cannabis and cannabinoids in the United States. *J Neurol Sci*. 2020;411: 116717.
47. Dean D, Passalacqua KD, Oh SM, Aaron C, Van Harn MG, King A. Pediatric cannabis single-substance exposures reported to the Michigan Poison Center from 2008–2019 after medical marijuana legalization. *J Emerg Med*. 2021;60(6): 701–8.
48. Krystal H. The misclassification of medical marijuana. *J Am Acad Psychiatry Law*. 2018;46(4):472–9.
- 49.● Wilkinson ST, Yarnell S, Radhakrishnan R, Ball SA, D'Souza DC. Marijuana legalization: impact on physicians and public health. *Annu Rev Med*. 2016;67(1):453–66. **This paper explores the contradictory arguments in support and against the legalization of cannabis.**
50. Hasin D, Walsh C. Trends over time in adult cannabis use: a review of recent findings. *Curr Opin Psychol*. 2021;38:80–5.
51. Wang GS. Pediatric concerns due to expanded cannabis use: unintended consequences of legalization. *J Med Toxicol*. 2017;13(1):99–105.
52. Andreyeva E, Ukert B. the impact of medical marijuana laws and dispensaries on self-reported health. *Forum for health economics and policy* [Internet]. 2019 Dec 18 [cited 2022 Sep 22];22(2). Available from: <https://www.degruyter.com/document/doi/10.1515/fhep-2019-0002/html>
53. Pacula RL, Smart R. Medical marijuana and marijuana legalization. *Annu Rev Clin Psychol*. 2017;13(1):397–419.
54. Shah A, Hayes CJ, Lakkad M, Martin BC. Impact of medical marijuana legalization on opioid use, chronic opioid use, and high-risk opioid use. *J GEN INTERN MED*. 2019;34(8):1419–26.
55. Weinstein LC, Worster B. Medical cannabis: a guide to the clinical and legal landscapes. *J Fam Pract*. 2019 Sep;68(7):390; 394;396;399.
56. Karst A. Weighing the benefits and risks of medical marijuana use: a brief review. *Pharmacy*. 2018;6(4):128.
57. Alharbi YN. Current legal status of medical marijuana and cannabidiol in the United States. *Epilepsy Behav*. 2020;112: 107452.
58. Kim JH, Brown D. Medical marijuana and the patient with chronic pain. *Topics in Pain Management*. 2019;34(12):1–8.
59. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. *Eur J Pharmacol*. 2007;556(1–3):75–83.
- 60.●● Busse JW, Wang L, Kamaleldin M, Craigie S, Riva JJ, Montoya L, et al. Opioids for chronic noncancer pain: a systematic review and meta-analysis. *JAMA*. 2018;320(23):2448. **This meta-analysis concludes that cannabinoids are just as effective as opioids for pain relief.**
61. Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. *Eur Arch Psychiatry Clin Neurosci*. 1990;240(1):1–4.
62. Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. *J Pain*. 2008;9(3):254–64.
63. Sohler NL, Starrels JL, Khalid L, Bachhuber MA, Arnsen JH, Nahvi S, et al. Cannabis use is associated with lower odds of prescription opioid analgesic use among HIV-infected individuals with chronic pain. *Subst Use Misuse*. 2018;53(10): 1602–7.
64. Noyes R, Brunk SF, Avery DH, Canter A. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. *Clin Pharmacol Ther*. 1975;18(1):84–9.
65. Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. *J Pain*. 2016;17(6):739–44.
66. Haroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, et al. The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study. *Clin J Pain*. 2016;32(12):1036–43.
67. Bar-Lev Schleider L, Mechoulam R, Lederman V, Hilou M, Lencovsky O, Betzalel O, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. *Eur J Intern Med*. 2018;49:37–43.
68. Candiotti KA, Gitlin MC. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? *Curr Med Res Opin*. 2010;26(7):1677–84.
69. Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. *Can Med Assoc J*. 2008;178(13):1669–78.
70. Metz TD, Allshouse AA, Hogue CJ, Goldenberg RL, Dudley DJ, Varner MW, et al. Maternal marijuana use, adverse pregnancy outcomes, and neonatal morbidity. *Am J Obstet Gynecol*. 2017;217(4):478.e1–478.e8.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.